Cargando…
In vitro analysis of PARP inhibitor nanoformulations
PARP-l is a DNA repair protein that plays a role in a number of repair pathways and also helps in transcriptional regulation; thus PARP inhibitors (PARPi), such as olaparib and BMN-673, act by inhibiting DNA damage repair. This leads to an accumulation of deleterious mutations leading to genetic ins...
Autores principales: | Baldwin, Paige, Tangutoori, Shifalika, Sridhar, Srinivas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5863639/ https://www.ncbi.nlm.nih.gov/pubmed/29593397 http://dx.doi.org/10.2147/IJN.S124992 |
Ejemplares similares
-
Intraperitoneal delivery of NanoOlaparib for disseminated late-stage cancer treatment
por: Baldwin, Paige, et al.
Publicado: (2018) -
Nanoformulation of Talazoparib Increases Maximum Tolerated Doses in Combination With Temozolomide for Treatment of Ewing Sarcoma
por: Baldwin, Paige, et al.
Publicado: (2019) -
Nanoformulation of Talazoparib Delays Tumor Progression and Ascites Formation in a Late Stage Cancer Model
por: Baldwin, Paige, et al.
Publicado: (2019) -
A nano-liposome formulation of the PARP inhibitor Talazoparib enhances treatment efficacy and modulates immune cell populations in mammary tumors of BRCA-deficient mice
por: Zhang, Di, et al.
Publicado: (2019) -
Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer
por: Yang, Shicheng, et al.
Publicado: (2023)